Hematology

Latest News

drug development in lab | Image credit: Nakron - stock.adobe.com
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity

November 29th 2023

A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.

blood stream
Phase 1 Study Finds Comparable PK, PD Parameters in Biosimilar GP40141 vs Reference Romiplostim

November 25th 2023

e vials filled with clear liquid and a syringe
Biosimilar, Innovator Romiplostim Comparably Safe and Effective

July 10th 2023

red blood cells and white blood cells
Samsung Bioepis' Eculizumab Biosimilar Approved in Europe

May 31st 2023

globe next to stethoscope
EU, Brazil Advance Hematology, Oncology Biosimilars

April 12th 2023

Latest CME Events & Activities

Advances in High-Risk Myelodysplastic Syndromes: Insights and Application for Managed Care With ASH Annual Meeting Coverage

1.0 Credit / Hematology, Oncology

View More

Perspectives on Sickle Cell Disease: Unique Clinical Needs for a Comprehensive, Coordinated Approach to Disease Management

1.0 Credit / Hematology, Rare Diseases

View More

Managed Care Insights on Optimizing the Use of BCMA-Targeted Treatments in Multiple Myeloma

1.5 Credits / Hematology, Oncology

View More

CAR T-Cell Therapy Advances in Lymphoma: Implications for Managed Care

1.5 Credits / Hematology, Oncology

View More

Evidence-Based Oncology: Discerning Novel Approaches, Recent Advances, and the Managed Care Considerations for Targeted Treatments in CLL

2.0 Credits / Hematology, Oncology

View More

Leveraging Managed Care to Increase Access to BCMA-Directed Treatment and Equitable Care in Multiple Myeloma

1.5 Credits / Hematology, Oncology

View More

New Pathways in Care for Myelofibrosis: Optimizing Treatment to Improve Outcomes

1.5 Credits / Hematology, Oncology

View More

Leveraging Managed Care to Optimize Patient Outcomes in Acute Myeloid Leukemia

1.5 Credits / Hematology, Oncology

View More

Managed Care Considerations on the Evolving Role of Bispecific Antibodies in Hematologic Malignancies

1.5 Credits / Hematology, Oncology

View More

Continuing the Conversation in Myelofibrosis: The Role of Managed Care in Supporting Treatment Goals Through Appropriate Use of Emerging Therapies

1.0 Credits / Hematology, Oncology

View More

Supporting Safe, Effective, and Equitable Access to B-Cell Maturation Antigen (BCMA)-Directed Treatments in Multiple Myeloma: Strategies for Specialty and Managed Care Pharmacists

1.5 Credit / Hematology, Oncology

View More

Advances in the Treatment of Myelofibrosis: Updates and Considerations for Managed Care Professionals

1.0 Credit / Hematology, Oncology

View More

© 2023 MJH Life Sciences

All rights reserved.